Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Phase 1 Active not recruiting 32 enrolled National Cancer Institute (NCI)

RandomizedParallel-groupTriple-blindPrevention

Summary

This randomized phase I trial studies the side effects and best dose of endoxifen hydrochloride in treating participants who are undergoing breast surgery. Endoxifen hydrochloride may treat or reduce the risk of breast cancer.

Timeline

Start: 2018-10-31
Primary completion: 2021-02-22
Completion: 2026-08-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Endoxifen	Small molecule	10 mg	Topical
Subject	Endoxifen	Small molecule	20 mg	Topical

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Summary

Timeline

Drugs

Indications